Skip to main content
Premium Trial:

Request an Annual Quote

Agilix Pockets $21M in Series B Financing Round

NEW YORK, Dec. 17 - Functional genomics and proteomics technology developer Agilix has closed a Series B financing round worth $20.8 million, the firm said on Monday.


Burrill & Company, Hambrecht & Quist Capital Management, Stephens Group, Wheatley MedTech Partners, and BioVeda participated in the round, which also included a reinvestment by Series A investor ATP Capital.


The capital will help Agilix, of New Haven, Conn., commercialize and ramp up production of its FAAST whole-transcriptome analysis system and its ZeptoLabeling technology for proteomic-based drug-discovery.


"We appreciate the industry's enthusiasm for our technologies and we look forward to scaling our production facilities to serve our discovery partners," Martin J. Mattessich, president & CEO of Agilix, said in a statement. "This is a fundamental change in the way companies approach both gene and protein expression profiling. These technologies will allow Agilix and our partners to study new genes, pathways, and toxicology profiles in any disease system and in any model organism."

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.